Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase 3 Trial of Imatinib for the Treatment of Pulmonary Arterial Hypertension (PAH)

Next Previous
X
Search
Trial Profile

A Pivotal Phase 3 Trial of Imatinib for the Treatment of Pulmonary Arterial Hypertension (PAH)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPROVE
  • Sponsors Tenax Therapeutics

    • Most Recent Events

    • 15 Sep 2022 According to a Tenax Therapeutics media release, the Company is shifting the anticipated launch of the imatinib Phase 3 trial in PAH, previously anticipated to begin in 2H 2022, into 2023.
    • 23 May 2022 According to a Tenax Therapeutics media release, the clinical sites of this study are now being recruited. Patient enrolment expected of this study is to start in 2H 2022.
    • 04 Jan 2022 According to a Tenax Therapeutics media release, the company has selected a large, global CRO partner. Planning efforts are underway, with KOL and site engagement expected to commence early this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top